{"id":796525,"date":"2026-03-17T19:38:01","date_gmt":"2026-03-17T19:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=796525"},"modified":"2026-03-17T19:38:01","modified_gmt":"2026-03-17T19:38:01","slug":"hodgkins-lymphoma-pipeline-expands-as-15-pharma-companies-advance-20-novel-therapies-toward-market-entry-finds-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hodgkins-lymphoma-pipeline-expands-as-15-pharma-companies-advance-20-novel-therapies-toward-market-entry-finds-delveinsight_796525.html","title":{"rendered":"Hodgkin&#8217;s Lymphoma Pipeline Expands as 15+ Pharma Companies Advance 20+ Novel Therapies Toward Market Entry, Finds DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/03\/1773673105.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hodgkin&#039;s Lymphoma Pipeline Expands as 15+ Pharma Companies Advance 20+ Novel Therapies Toward Market Entry, Finds DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/03\/1773673105.jpg\" alt=\"Hodgkin&#039;s Lymphoma Pipeline Expands as 15+ Pharma Companies Advance 20+ Novel Therapies Toward Market Entry, Finds DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Hodgkin&#8217;s Lymphoma \u2013 Pipeline Insight, 2026<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Hodgkin&#8217;s Lymphoma \u2013 Pipeline Insight, 2026&#8221; report provides comprehensive insights about 15+ companies, including Merck Sharp &#038; Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics, and others, developing several pipeline drugs in the Hodgkin&#8217;s Lymphoma pipeline landscape.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<strong>Hodgkin&#8217;s Lymphoma &ndash; Pipeline Insight, 2026<\/strong>&#8221; report provides comprehensive insights about 15+ companies developing several pipeline drugs in the Hodgkin&#8217;s Lymphoma pipeline landscape. It covers the Hodgkin&#8217;s Lymphoma pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><em>Explore the latest breakthroughs in the Hodgkin&#8217;s Lymphoma treatment landscape. Learn more about the evolving Hodgkin&#8217;s Lymphoma pipeline today @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">https:\/\/www.delveinsight.com\/sample-request\/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr<\/a><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Hodgkin&#8217;s Lymphoma Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>DelveInsight&#8217;s Hodgkin&#8217;s Lymphoma Pipeline Insight report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Hodgkin&#8217;s Lymphoma treatment.<\/p>\n<\/li>\n<li>\n<p>The leading Hodgkin&#8217;s Lymphoma companies include <strong>Merck Sharp &amp; Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics, and others.<\/strong><\/p>\n<\/li>\n<li>\n<p>The companies which have their Hodgkin&#8217;s Lymphoma drug candidates in the most advanced stage include Affimed Therapeutics, which is evaluating AFM13 in Phase II clinical trials.<\/p>\n<\/li>\n<li>\n<p><strong>AFM13 by Affimed Therapeutics<\/strong> is a first-in-class innate cell engager (ICE&reg;) designed to activate the innate immune system against CD30-positive hematologic tumors, currently in Phase II clinical evaluation for Hodgkin&#8217;s Lymphoma.<\/p>\n<\/li>\n<li>\n<p><strong>AUR105 by Aurigene Oncology<\/strong>, a small molecule targeting PRMT5, is in Phase I clinical evaluation for Hodgkin&#8217;s Lymphoma, with potential across multiple hematologic malignancies.<\/p>\n<\/li>\n<li>\n<p>The Hodgkin&#8217;s Lymphoma pipeline features therapies spanning multiple mechanisms including checkpoint inhibitors, antibody-drug conjugates, targeted small molecules, and innate immune cell engagers, reflecting diversified R&amp;D approaches.<\/p>\n<\/li>\n<li>\n<p>Global coverage is provided in the Hodgkin&#8217;s Lymphoma Pipeline Insight, 2026 report, encompassing late-stage, mid-stage, early-stage, preclinical, and discovery-stage pipeline products.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><em>Download for updates and the latest revolution in Hodgkin&#8217;s Lymphoma care @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">Hodgkin&#8217;s Lymphoma Market Insight<\/a><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Hodgkin&#8217;s Lymphoma Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>AFM13: Affimed Therapeutics<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">AFM13 is a first-in-class innate cell engager (ICE&reg;) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors. AFM13 induces specific and selective killing of CD30-positive tumor cells, leveraging the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages. AFM13 is a tetravalent bispecific innate cell engager designed to act as a bridge between the innate immune cells and the tumor, creating the necessary proximity for the innate immune cells to specifically destroy the tumor cells. The most advanced ICE&reg; clinical program, AFM13 was evaluated as monotherapy in a Phase IIB trial (REDIRECT) in patients with relapsed\/refractory peripheral T cell lymphoma, achieving an ORR of 32.4% with a well-managed safety profile. Currently, AFM13 is in Phase II stage of clinical trial evaluation for the treatment of Hodgkin&#8217;s Lymphoma.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>AUR105: Aurigene Oncology<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">AUR105 is a small molecule that acts by targeting protein arginine methyltransferase 5 (PRMT5). The drug candidate is also under development for other indications including solid tumors, non-Hodgkin lymphoma, and leukemia. AUR105 is administered through the oral route, offering a convenient dosing option for patients. Currently, the drug is being evaluated in Phase I for the treatment of Hodgkin&#8217;s Lymphoma.<\/p>\n<p style=\"text-align: justify;\"><em>For more information on the Hodgkin&#8217;s Lymphoma Emerging Drugs Profile, download DelveInsight&#8217;s comprehensive Hodgkin&#8217;s Lymphoma Pipeline Insight report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">Hodgkin&#8217;s Lymphoma Emerging Drugs<\/a><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>The Hodgkin&#8217;s Lymphoma Pipeline Report Provides<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Detailed insights about companies developing therapies for Hodgkin&#8217;s Lymphoma, with aggregate therapies developed by each company.<\/p>\n<\/li>\n<li>\n<p>Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Hodgkin&#8217;s Lymphoma treatment.<\/p>\n<\/li>\n<li>\n<p>Hodgkin&#8217;s Lymphoma companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>Hodgkin&#8217;s Lymphoma drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, different mechanism of action, and molecular type.<\/p>\n<\/li>\n<li>\n<p>Detailed analysis of collaborations (company&ndash;company and company&ndash;academia), licensing agreements, and financing details for future advancement of the Hodgkin&#8217;s Lymphoma market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><em>Learn more about Hodgkin&#8217;s Lymphoma drug opportunities in our comprehensive pipeline report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">Hodgkin&#8217;s Lymphoma Unmet Needs<\/a><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Hodgkin&#8217;s Lymphoma Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">There are 15+ key companies, such as Merck Sharp &amp; Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics, and others, developing therapies for Hodgkin&#8217;s Lymphoma, with Affimed Therapeutics having its Hodgkin&#8217;s Lymphoma drug candidate AFM13 in the most advanced Phase II stage.<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&#8217;s Hodgkin&#8217;s Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Parenteral<\/p>\n<\/li>\n<li>\n<p>Intravenous<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Topical<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Hodgkin&#8217;s Lymphoma products have been categorized under various Molecule types such as:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Monoclonal Antibody<\/p>\n<\/li>\n<li>\n<p>Peptides<\/p>\n<\/li>\n<li>\n<p>Polymer<\/p>\n<\/li>\n<li>\n<p>Small Molecule<\/p>\n<\/li>\n<li>\n<p>Gene Therapy<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><em>Discover the latest advancements in Hodgkin&#8217;s Lymphoma treatment by visiting our website. Stay informed @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">Hodgkin&#8217;s Lymphoma Market Drivers and Barriers<\/a><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Hodgkin&#8217;s Lymphoma Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Coverage:<\/strong> Global<\/p>\n<\/li>\n<li>\n<p><strong>Hodgkin&#8217;s Lymphoma Companies:<\/strong> Merck Sharp &amp; Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics, and others<\/p>\n<\/li>\n<li>\n<p><strong>Hodgkin&#8217;s Lymphoma Therapies:<\/strong> AFM13, AUR105, and other pipeline candidates across Phase III, Phase II, Phase I, preclinical, and discovery stages<\/p>\n<\/li>\n<li>\n<p><strong>Therapeutic Assessment by Product Type:<\/strong> Mono, Combination, Mono\/Combination<\/p>\n<\/li>\n<li>\n<p><strong>Therapeutic Assessment by Clinical Stages:<\/strong> Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>\n<p>Introduction<\/p>\n<\/li>\n<li>\n<p>Executive Summary<\/p>\n<\/li>\n<li>\n<p>Hodgkin&#8217;s Lymphoma: Overview<\/p>\n<\/li>\n<li>\n<p>Pipeline Therapeutics<\/p>\n<\/li>\n<li>\n<p>Therapeutic Assessment<\/p>\n<\/li>\n<li>\n<p>Hodgkin&#8217;s Lymphoma &ndash; DelveInsight&#8217;s Analytical Perspective<\/p>\n<\/li>\n<li>\n<p>Late Stage Products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid Stage Products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early Stage Products (Phase I)<\/p>\n<\/li>\n<li>\n<p>Preclinical and Discovery Stage Products<\/p>\n<\/li>\n<li>\n<p>Inactive Products<\/p>\n<\/li>\n<li>\n<p>Hodgkin&#8217;s Lymphoma Key Companies<\/p>\n<\/li>\n<li>\n<p>Hodgkin&#8217;s Lymphoma Key Products<\/p>\n<\/li>\n<li>\n<p>Hodgkin&#8217;s Lymphoma Unmet Needs<\/p>\n<\/li>\n<li>\n<p>Hodgkin&#8217;s Lymphoma Market Drivers and Barriers<\/p>\n<\/li>\n<li>\n<p>Hodgkin&#8217;s Lymphoma Future Perspectives and Conclusion<\/p>\n<\/li>\n<li>\n<p>Hodgkin&#8217;s Lymphoma Analyst Views<\/p>\n<\/li>\n<li>\n<p>Appendix<\/p>\n<\/li>\n<\/ol>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Arpit Anand<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hodgkins-lymphoma-pipeline-expands-as-15-pharma-companies-advance-20-novel-therapies-toward-market-entry-finds-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hodgkins-lymphoma-pipeline-expands-as-15-pharma-companies-advance-20-novel-therapies-toward-market-entry-finds-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hodgkin&#8217;s Lymphoma \u2013 Pipeline Insight, 2026 DelveInsight&#8217;s &#8220;Hodgkin&#8217;s Lymphoma \u2013 Pipeline Insight, 2026&#8221; report provides comprehensive insights about 15+ companies, including Merck Sharp &#038; Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics, and others, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hodgkins-lymphoma-pipeline-expands-as-15-pharma-companies-advance-20-novel-therapies-toward-market-entry-finds-delveinsight_796525.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-796525","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/796525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=796525"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/796525\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=796525"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=796525"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=796525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}